In the course of our screening for inhibitors of sphingosine kinase, we found two active compounds in a culture broth of a fungus, Zopfiella inermis SANK15 1 83. The structures of the compounds, named S-15183a and b, were elucidated by a combination of spectroscopic analyses to be new azaphilone-type metabolites. S-15183a and b inhibited sphingosine kinase from rat liver with IC50 values of 2.5 and 1.6jim, respectively. S-15183a also inhibited endogenous SPHkinase activity in intact platelets.
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Sphingosine-1-phosphate (SPP) was initially described as an intermediate in the metabolic pathway of long-chain sphingoid basesl\ However, it is now widely accepted to be a unique bioactive lipid messenger. It acts as a second messenger to regulate proliferation and survival intracellulary, and as a ligand for G protein-coupled receptors of the Edg-1 sub family extracellularly2 '3) . SPP is involved in a variety of cellular functions, including vascular maturation4), angiogenesis5), TNF-a signalling6), mediation of Fc£RI signaling in mast cells7), nerve growth factor-mediated neuronal survival and differentiation8r egulation of cell motility9' 10), platelet activation11}, activation of muscarinic K+ currents12), neurite retraction13) and cell proliferation, especially in signal transduction pathways of platelet-derived growth factor (PDGF) 14 ' 15) .
Sphingosine kinase, which catalyzes phosphorylation of sphingosine (SPH) on its primary hydroxyl group, is a key enzyme that regulates the cellular SPP Ievel16 '17) .
Intervention of SPH kinase activity with specific inhibitors may give us insight into the regulation mechanism of SPH kinase and the roles of SPP Moreover, these inhibitors may have clinical value, since SPP generation has been implicated in pathogenic states such as angiogenesis4 '5) arteriosclerosis9 ' 14) , thrombosis1 U8), and inflammation6' 7).
pp. 415 -420 SPH analogs, such as D,L-£/zreo-dihydroSPH and N,NdimethylSPH (DMS), have been used as SPH kinase inhibitors7 ' 14' 18) .
However, due to structural similarity to SPH, they are also reported to have several other physiological functions19^21) which may not be responsible for SPH kinase inhibition. Thus, specific inhibitors for SPH kinase are desired. Wetherefore screened for inhibitors of SPHkinase, and have previously isolated novel SPH kinase inhibitors, named F-12509A22) and B-5354s23'24) .
Continuing efforts to screen new SPHkinase inhibitors led to the discovery of new compounds, named S-15183a and b (Fig. 4) SPH Kinase Assay in a Cell-free System As the source of SPHkinase, we used rat liver cytosol as previously described22). For the assay of SPH kinase activity in a cell-free system, we used the method of Louie et al.25^with some modifications as previously described22).
[ 
Isolation
The isolation procedure for S-15183a and b is summarized in Fig. 1 
Structure Determination
The physico-chemical data suggested that S-15183a and b are closely related to each other, and structural studies were first carried out on the major component S-15183a. In the *H NMRof S-15183a, resonances arising from three olefinic protons (5H 7.88, 6.09 and 5.52) and a singlet methyl group (5H 1.52) were observed. The 13C NMRand DEPT spectra showed the presence of a linear saturated fatty acid ester and two earbonyl carbons (<5C 193.5, 192.9) . A literature search revealed that these data were similar to those of a known azaphilone, daldinin A29). The presence of the chromophore was supported by the UVand IR spectral data (vide supra). In consideration of the molecular formula, C27H36O5, the structure of S-15183a was proposed as shown in Fig. 2 , while m and n values remained to be solved due to the signal overlap in the aliphatic region of !H NMR.
Azaphilones are known to give isochroman derivatives by catalytic hydrogenation30). As expected, S-15183a was converted to an isochroman-type compound by hydrogenation over 10% palladium carbon under atmospheric pressure at room temperature. The product was purified by preparative TLC and the hydrogenation product structure is shown in Fig. 3 . Taking into account the molecular formula C27H36O5, only the gross structure of S-15183a could be proposed at this stage leaving the side chain mand n values yet to be determined due to overlapping signals in the *H NMR.Since S-15183b differs from S-15183a only in an increase of 2XCH2units, the final structures could not be confirmed by NMRalone. The chain lengths were established for both S-15183a and b by reduction of each compound to the isochroman. In each case the same hydrogenated compound was produced possessing the same C-3 side chain. Therefore if the C-3 side chain contains seven carbones in S-15183a, this leaves C-7 side chain as an octanoate and in S-15183b the side chain is therefore a decanoate, to account for the difference in molecular weight. The structure of the isochroman derivative was determined as shown in Fig. 3 , therefore, the structures of S-15183a and b were determined as shown in 
SPH Kinase Inhibitory Activity in a Cell-Free System
Weevaluated effects of the S-15183s on rat liver SPH kinase activity in a cell-free system. As shown in Fig. 5 , S15183a and b inhibited the SPH kinase in a dose-dependent manner, with IC50 values of2.5 and 1.6 /zm, respectively. As a positive control, DMS18) inhibited the SPH kinase with an IC50 value of 1.0 flu in the assay system. Fig. 6 , S-l5183a inhibited the SPP formation in a dose-dependent mannereven when added extracellularly. The result suggests that S-l5183a permeates the plasma membrane and inhibits SPH kinase in intact cells. In a control study, DMSalso inhibited SPP formation.
Specificity
In order to assess the specificity, we evaluated the effects of S-l5183a on other sphingolipid metabolic enzyme, neutral SMase, and on other kinases, PI 3-kinase and PKC. S-l5183a showed virtually no inhibitory activity towards any of the enzymes even at 100^M. These results indicate that S-l5183a is a specific inhibitor ofSPH kinase. In summary, S-15183a, a new azaphilone, is a potent and specific inhibitor of mammalian SPH kinase. S-l 5 1 83a may be an effective tool in understanding the role of SPP in the cellular physiological functions.
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